1.Comparison of Formulation Property and Therapeutic Safety of Paclitaxel between Generic Products
Hiroyuki Ono ; Yuhki Sato ; Nobuhiro Oyama ; Ryosuke Nakahara ; Masae Kuranari ; Hiroki Itoh
Japanese Journal of Drug Informatics 2016;18(1):7-12
Background: Because generic medicines reduce the financial burden on patients and medical insurance providers, they become more popular year after year. However, there are still few reports that analyze the efficacy and safety of generic medicines, especially in terms of their characteristics and side effects.
Methods: Paclitaxel is an antineoplastic frequently used with good results in the treatment of breast cancer, ovarian cancer, gastric cancer, and angiosarcoma, but fat solubility is high and various kinds of adverse events, such as myelosuppression and arthralgia, peripheral neuropathy, and alcohol hypersensitivity are known to develop. We investigated the efficacy, characteristics, and the incidence of adverse events for the generic product of paclitaxel.
Results: Differences were found for the generic version in terms of the characteristics and preparation time.
Conclusion: The incidence of adverse events was not significant, suggesting that the generic version could be a reasonable substitute.
2.Questionnaire Survey on the Satisfaction of Ophthalmic Solutions and the Handling of Eye Drops in Patients with Ophthalmic Diseases
Yuko ONO ; Yuhki SATO ; Daiki ETO ; Hiroki ITOH
Japanese Journal of Drug Informatics 2021;22(4):202-206
Clarifying the current state of ophthalmic solutions and the handling of eye drops is important for the proper use of ophthalmic solutions. In this study, a questionnaire survey was conducted from May 2018 to February 2019 on 200 ophthalmic inpatients who provided consent. In total, 36.5% of the patients were dissatisfied with the usability of ophthalmic containers due to their hard material andthe difficulty of releasing the ophthalmic solution. In addition, 43.0% of the patients repliedthat they hadlearnedfrom medical professionals, such as doctors and pharmacists, about the handling of eye drops, whereas 45.0% reported failing to apply ophthalmic solutions onto their eyes correctly. Only 2.0% of the respondents answeredthat they hadconsulteddoctors or pharmacists about the use of ophthalmic solutions. These findings underscore the current problems about patients’ satisfaction with ophthalmic solutions andhandling of eye drops. Therefore, pharmacists may needto be actively involvedin patients’ selection of ophthalmic solutions andinstruct them regarding usage.